Results 91 to 100 of about 6,879 (203)
Efficacy of rimonabant in obese patients with binge eating disorder
In obesity, a dysregulation of the endocannabinoid system has been shown. The endocannabinoid receptor blockage by rimonabant demonstrated interesting metabolic effects.
Gasteyger, Curt +11 more
core +1 more source
peer reviewedRimonabant (Acomplia) is the first selective CB1 receptor blocker of the endocannabinoid system. It has been evaluated in the RIO ("Rimonabant In Obesity and related disorders") programme including above 6.600 overweight/obese patients with ...
Van Gaal, L. F., Scheen, André
core
Risk of Depressive Episodes with Rimonabant
Background: Marketing authorization for rimonabant was withdrawn in October 2008, mainly because the psychiatric adverse effects could not be addressed by further risk minimization.Objective: The aim of the study was to compare the risk of major and ...
Lynda Wilton +7 more
core +1 more source
Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice
Objectives It has been recently reported that blockade of type 1 cannabinoid (CB1) receptors by specific antagonists or genetic manipulation alleviates dyslipidaemia, hyperglycaemia and insulin resistance in animal models of obesity and
Satinder Singh +7 more
core +1 more source
Rimonabant improves hepatic steatosis in OLETF rats.
(A) Representative hematoxylin and eosin-stained liver sections (scale bars, 200 μm; magnification, 200 X). (B) NAFLD activity score. Representative images of Masson’s trichrome staining (C; scale bars, 100 μm; magnification, 400 X) and fibrosis score (D)
Hyekyung Yang (2461081) +5 more
core +1 more source
A simple, accurate, and precise HPLC method was developed and validated for determination of rimonabant in human plasma. Following liquid-liquid extraction, chromatographic separation was accomplished using C18 column with mobile phase consisting of ...
Shravan Bankey +5 more
doaj +1 more source
Rimonabant: the first therapeutically relevant cannabinoid antagonist
The present paper synthetically reviews the multiple experimental lines of evidence indicating the ability of the prototypic cannabinoid CB1 receptor antagonist, rimonabant (also known as SR 141716), to suppress the reinforcing/rewarding properties of ...
Gessa GL, Colombo G, Carai MAM
core +1 more source
Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents
The selective CB1 receptor antagonist rimonabant is a novel weight control agent. Although CB1 receptors and binding sites are present in both the rodent central and peripheral nervous systems, including the afferent vagus nerve, the role of gut ...
Larsen, Philip J +5 more
core +1 more source
Rimonabant (SR141716) and the structurally related AM251 are widely used in pharmacological experiments as selective cannabinoid receptor CB(1) antagonists / inverse agonists. Concentrations of 0.5-10 µM are usually applied in in vitro experiments.
Baur, R +11 more
core +1 more source

